Today, the Chief Financial and of Bluebird Bio (BLUE), Jeffrey T. Walsh, bought shares of BLUE for $36.71K.
Following Jeffrey T. Walsh’s last BLUE Buy transaction on January 09, 2019, the stock climbed by 23.8%. This is Walsh’s first Buy trade following 4 Sell transactions.
See today’s analyst top recommended stocks >>
Based on Bluebird Bio’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $11.53 million and GAAP net loss of $145 million. In comparison, last year the company earned revenue of $4.17 million and had a GAAP net loss of $117 million. Currently, Bluebird Bio has an average volume of 363.7K.
Based on 12 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $147.14, reflecting a 8.8% upside. Seven different firms, including Bernstein and Canaccord Genuity, currently also have a Buy rating on the stock.
The insider sentiment on Bluebird Bio has been negative according to 69 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
bluebird bio, Inc. is a clinical-stage biotechnology company. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. It offers the LentiGlobin which is a treatment for transfusion-dependent ß-thalassemia; and Lenti-D as a treatment for cerebral adrenoleukodystrophy.
